{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:52:26Z","timestamp":1794430346332,"version":"4.9.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1001\/jamaophthalmol.2020.2699","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T15:52:18Z","timestamp":1596124338000},"page":"964","source":"Crossref","is-referenced-by-count":187,"title":["Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"138","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[{"name":"Sierra Eye Associates, Reno, Nevada"},{"name":"Reno School of Medicine, University of Nevada, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Patel","sequence":"additional","affiliation":[{"name":"West Texas Retina Consultants, Abilene"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Ferrone","sequence":"additional","affiliation":[{"name":"Long Island and Queens Vitreoretinal Consultants, PC, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Osborne","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"},{"name":"now with Adverum Biotechnologies Inc, Menlo Park, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sahni","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffmann-La Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Grzeschik","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Basu","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"},{"name":"now with Roche Products (Ireland), Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"},{"name":"now with Kodiak Sciences Inc, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Haskova","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin U.","family":"Dugel","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Arizona, Phoenix"},{"name":"USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles"},{"name":"now with IVERIC bio, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi200055r1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy.","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"2-a suppl","key":"eoi200055r3","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration.","volume":"24","author":"Wykoff","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"eoi200055r4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ceo.2018.46.issue-4","article-title":"Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.","volume":"46","author":"Ozturk","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"eoi200055r5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92?976 ranibizumab injections: report 1: visual acuity.","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200055r6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi200055r7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"issue":"6","key":"eoi200055r8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/aos.2013.91.issue-6","article-title":"Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study: a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.","volume":"91","author":"Finger","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"eoi200055r9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States.","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"eoi200055r10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129361","article-title":"Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration.","volume":"10","author":"Gohil","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"eoi200055r11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study.","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"eoi200055r12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/OPTH","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey.","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"eoi200055r13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/eye.2015.235","article-title":"Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration.","volume":"30","author":"Vukicevic","year":"2016","journal-title":"Eye (Lond)"},{"issue":"11","key":"eoi200055r14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"5","key":"eoi200055r15","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910666","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.","volume":"11","author":"Regula","year":"2019","journal-title":"EMBO Mol Med"},{"key":"eoi200055r16","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial.","author":"Sahni","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi200055r17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway.","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"eoi200055r18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases.","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"eoi200055r19","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"8","key":"eoi200055r20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial.","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi200055r21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"eoi200055r23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I trial of anti\u2013vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration.","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"eoi200055r24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi200055r25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200055r26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200055r27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi200055r28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration: a phase IV randomised clinical trial with ranibizumab: the FLUID study.","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"eoi200055r29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials.","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi200055r2","unstructured":"American Academy of Ophthalmology. Age-related macular degeneration PPP 2019. Published October 2019. Accessed January 15, 2020. https:\/\/www.aao.org\/preferred-practice-pattern\/age-related-macular-degeneration-ppp"},{"key":"eoi200055r22","unstructured":"US Food and Drug Administration. Regulations: good clinical practice and clinical trials. Accessed June 26, 2020. https:\/\/www.fda.gov\/science-research\/clinical-trials-and-human-subject-protection\/regulations-good-clinical-practice-and-clinical-trials"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2768857\/jamaophthalmology_khanani_2020_oi_200055_1600873409.8708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T11:01:12Z","timestamp":1600945272000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2768857"}},"subtitle":["The STAIRWAY Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}